Q-omics provides the consensus-scored BRD7P6 profile across patient tissues and cancer cell-line models. BRD7P6 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, BRD7P6 is differentially expressed in 4, with the highest sampling consensus in HNSC. Additionally, BRD7P6 RNA expression shows 6,130 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight UVM, HNSC, and STAD as cancer lineages where BRD7P6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BRD7P6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BRD7P6 survival associations across molecular data types. BRD7P6 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BRD7P6 RNA expression–survival associations across cancer types. High BRD7P6 expression shows unfavorable associations in UVM, THCA, LUSC, DLBC, ACC and LIHC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify UVM as the clearest survival context for BRD7P6 RNA expression.
This table summarizes BRD7P6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for BRD7P6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BRD7P6 shows lower tumor expression in BRCA and higher tumor expression in HNSC, LUSC and LUAD. The HNSC box plot shows higher BRD7P6 RNA expression in tumor versus normal tissue (log2 FC = +0.043, t-test p < 0.001).
This table shows molecular features associated with BRD7P6 in patient tissues and cancer cell lines. In patient samples, BRD7P6 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
